What do electric boats and AI cancer treatment have in common?

Investor excitement 🕺                                                                                                                                                                                                                                                                                                                                                                                                                  Good morning, 360! Here are our top investing ideas today – and don’t forget Jeff is offering complimentary 🎯Bullseye training at 11AM EST TODAY —> [join his room here at 11!]( FRZA - Up over 100% in pre-market after cryptic tweet EVAX - Up over 40% after company announced its Melanoma trial met its primary endpoints using proprietary AI technology DAWN - Up over 20% after announcing positive new data from registrational Phase 2 trial for treatment of pediatric low-grade Giloma *A Message on Behalf of Energy Sector Report 🔥 Hot Stock of the Day 🔥 Dragonfly Energy (Nasdaq: DFLI) Recently, Elon Musk bluntly said that [battery shortage]( is the one thing holding back Tesla. But did you know there is a small, US-based company that is tackling this problem head-on? Dragonfly Energy (DFLI) is a premier manufacturer of next-gen battery solutions. Right now, the stock is trading at a massive discount to what the average analyst projections are on it… DFLI has a history of making some very fast moves, so do yourself a favor and learn more about it by reading this quick report our friends at [Energy Sector Reports]( have published. Make sure you don’t ignore these alerts… some of them have been absolute 🔥 lately! Pay close attention to DFLI this week and see if you love it as much as we do! *Sponsored by Lifewater Media. Please see disclosures below. FRZA - Up over 100% in pre-market after cryptic tweet Forza X1 (FRZA) focuses on designing, developing and manufacturing electric boats in the United States. Shares traded up over 100% this morning after the company tweeted on Friday, “Get ready for something extraordinary! Stay tuned!” The stock IPO’d late last year and was trading above $14 before trading in the low 1’s. The company [has a low float of less than 4 million shares according to Finviz](. Expect plenty of volatility in this one today. $2.80 was resistance in the after-hours and is being tested again in the pre-market. That is an important level to watch today. Above it, targets to the upside are $3, $3.50, $4, $4.50, $5 and then $6. Below $2.80, there is potential support at $2.60, $2.40, $2.20 , $1.80 with a gap to fill at $1.25. EVAX - Up over 40% after company announced its Melanoma trial met its primary endpoints using proprietary AI technology Evaxion Biotech (EVAX) is a clinical-stage biotech company, that engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases and viral infections. The company announced its Phase 1 Melanoma trial met its primary endpoints. Moreover, the company announced its AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients. Strong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients. $2.10 has been an area of support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.24, $2.34, and then the pre-market high of $2.44. Beyond that, targets are $2.60, $2.70, $3 with $3.20, $3.40 and $3.50 above that. Below $2.10, there is potential support at $2, $1.92, $1.80, $1.60 and a gap to fill at $1.48. DAWN - Up over 20% after announcing positive new data from registrational Phase 2 trial for treatment of pediatric low-grade Giloma Day One Biopharmaceuticals (DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced new data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent Tovorafenib (DAY101). DAWN announced over the weekend an overall response rate of 67% and clinical benefit rate of 93% in 69 heavily heavily pretreated RANO-HGG evaluable patients in a pediatric low-grade glioma trial. The stock is up over 20% in the pre-market on the news, trading above $16. Needham reiterated its Buy rating on DAWN, maintaining its $40 price target, and HC Wainwright & Co maintained its Buy and raised its price target to $50. $16.50 was a support level in the pre-market and will be an important level to watch. Above it, targets to the upside are $18, $18.60 and then the pre-market high of $18.89. Beyond that, $19.50, $20.50, $21.50 and $22 come into play. Below $16.50, there is potential support at $15.70, $15.20, $14 and then a gap to fill at $13.60. [Economic Calendar]( To Your Success! *Please see disclosures below. Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid nineteen thousand dollars by ach bank transfer by Lifewater Media for advertising Dragonfly Energy from a period beginning on June 5, 2023 through June 6 of the same year. Previously, RagingBull has been paid fourteen thousand dollars by ach bank transfer by Lifewater Media for advertising Dragonfly Energy from a period beginning on April 12, 2023 through April 13 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Dragonfly Energy. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Dragonfly Energy, increased trading volume, and possibly an increased share price of the Dragonfly Energy securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: //www .sec. gov/ edgar/ searchedgar/ companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull. com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](